Cisapride - Drug interactions of clinical significance

被引:66
作者
Bedford, TA
Rowbotham, DJ
机构
[1] Department of Anaesthesia, Leicester Royal Infirmary NHS Trust, Leicester
[2] Department of Anaesthesia, Leicester Royal Infirmary NHS Trust
关键词
D O I
10.2165/00002018-199615030-00002
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Cisapride is a prokinetic agent which restores motility of the gastrointestinal tract in conditions of decreased bowel transit, It may also alter the absorption of coadministered drugs. The absorption of morphine, diazepam, cyclosporin, alcohol (ethanol) and levodopa are increased, Initial absorption of cimetidine and raniditine is also increased, but overall absorption is lower due to increased bowel transit, The absorption of digoxin, propranolol and the anticoagulants warfarin and phenprocoumon appears unaffected by cisapride, although increase thrombotest values were seen with acenocoumarol (nicoumalone). Drug interactions leading to increased plasma concentrations of cisapride may produce an increase in adverse effects, The most important of these is QT interval prolongation and ventricular arrhythmias. Phenytoin does not appear to affect protein binding of cisapride, Cisapride metabolism is inhibited by the antifungals ketoconazole, fluconazole, itraconazole and miconazole, and by the antibacterials erythromycin, troleandomycin and clarithromycin. Cisapride should not be coadministered with these drugs. Cimetidine produces a small increase in cisapride plasma concentrations, which may be due to inhibition of metabolism. Cisapride absorption is unaffected by other antacids. Atropine may reverse the cisapride-induced increase in peristalsis. Prescribers should remain vigilant to the presence of these and other, as yet unreported, reactions.
引用
收藏
页码:167 / 175
页数:9
相关论文
共 31 条
[11]  
*JANSS PHARM, 1995, CIS
[12]   EFFECTS ON THE LOWER ESOPHAGEAL SPHINCTER OF CISAPRIDE GIVEN BEFORE THE COMBINED ADMINISTRATION OF ATROPINE AND NEOSTIGMINE [J].
JONES, MJ ;
MITCHELL, RWD ;
HINDOCHA, N .
BRITISH JOURNAL OF ANAESTHESIA, 1989, 62 (02) :124-128
[13]  
JONKER JJC, 1985, R51619NL JANSS PHARM
[14]  
KIRCH W, 1989, THER DRUG MONIT, V11, P411
[15]   EFFECT OF CISAPRIDE AND METOCLOPRAMIDE ON DIGOXIN BIOAVAILABILITY [J].
KIRCH, W ;
JANISCH, HD ;
SANTOS, SR ;
DUHRSEN, U ;
DYLEWICZ, P ;
OHNHAUS, EE .
EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 1986, 11 (04) :249-250
[16]   THE INFLUENCE OF RECTAL CISAPRIDE ON MORPHINE-INDUCED GASTRIC STASIS [J].
KLUGER, MT ;
PLUMMER, JL ;
OWEN, H .
ANAESTHESIA AND INTENSIVE CARE, 1991, 19 (03) :346-350
[17]   EFFECTS OF CISAPRIDE ON GASTROINTESTINAL MOTOR-ACTIVITY AND GASTRIC-EMPTYING OF DISOPYRAMIDE [J].
KURODA, T ;
YOSHIHARA, Y ;
NAKAMURA, H ;
AZUMI, T ;
INATOME, T ;
FUKUZAKI, H ;
TAKANASHI, H ;
YOGO, K ;
AKIMA, M .
JOURNAL OF PHARMACOBIO-DYNAMICS, 1992, 15 (08) :395-402
[18]   CISAPRIDE - A PRELIMINARY REVIEW OF ITS PHARMACODYNAMIC AND PHARMACOKINETIC PROPERTIES, AND THERAPEUTIC USE AS A PROKINETIC AGENT IN GASTROINTESTINAL MOTILITY DISORDERS [J].
MCCALLUM, RW ;
PRAKASH, C ;
CAMPOLIRICHARDS, DM ;
GOA, KL .
DRUGS, 1988, 36 (06) :652-681
[19]  
MOENIG H, 1989, EUR J CLIN PHARMACOL, V36, pPA117
[20]   THE EFFECTS OF CISAPRIDE ON PLASMA L-DOPA LEVELS AND CLINICAL-RESPONSE IN PARKINSONS-DISEASE [J].
NEIRA, WD ;
SANCHEZ, V ;
MENA, MA ;
DEYEBENES, JG .
MOVEMENT DISORDERS, 1995, 10 (01) :66-70